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Abstract
Background: Warfarin is used for the prevention of stroke in chronic atrial fibrillation. The
product has a narrow therapeutic index and to obtain treatment success, patients must be
maintained within a given therapeutic range (International Normalised Ratio;INR). To ensure a wise
allocation of health care resources, scrutiny of costs associated with various treatments is justified.
The objective of this study was to estimate the health care cost of INR controls in patients on
warfarin treatment with chronic atrial fibrillation in primary care in Sweden.
Methods: Data from various sources were applied in the analysis. Resource consumption was
derived from two observational studies based on electronic patient records and two Delphi-panel
studies performed in two and three rounds, respectively. Unit costs were taken from official
databases and primary health care centres.
Results: The mean cost of one INR control was SEK 550. The mean costs of INR controls during
the first three months, the first year and during the second year of treatment were SEK 6,811, SEK
16,244 and SEK 8,904 respectively.
Conclusion: INR controls of patients on warfarin treatment in primary care in Sweden represent
a substantial cost to the health care provider and they are particularly costly when undertaken in
home care. The cost may however be off-set by the reduced incidence of stroke.
Background
The prevalence of chronic atrial fibrillation (CAF) has
been estimated at 1% of the total population of Sweden
[1,2], and a recent study demonstrated a prevalence of 0.6
in primary health care [3]. The corresponding figure from
the U.S. for the occurrence of atrial fibrillation has been
estimated at 0.9 [4,5]. The prevalence of AF increases as
patients grow older. Atrial fibrillation is a potentially dis-
abling and fatal disorder, due to an annual incidence of
stroke of 5% [6]. Of all ischemic strokes, about 16% are
related to non-valvular AF, and in patients over 75 years
of age this frequency increases to one third [6].
Oral anticoagulant drugs, i.e. vitamin K antagonists, are
used for the prevention of stroke in CAF and their efficacy
has been demonstrated in a large number of studies [6].
However, warfarin has a narrow therapeutic index and to
obtain treatment success, the patients must be maintained
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within a given therapeutic range. This is defined as the
International Normalised Ratio (INR) and the most com-
monly recommended range is INR 2–3. If the INR is
below range, the patient will be at risk of thromboembo-
lism and if the INR is above range, the patients will be at
risk of experiencing a hemorrhagic event. Furthermore,
warfarin interacts with certain types of food, alcohol and
many other drugs. Thus the management of patients on
warfarin requires frequent monitoring and dose adjust-
ment in order to maximise the time the patient spends
within the therapeutic INR range. In Sweden, such con-
trols are usually carried out in dedicated anticoagulation
clinics in hospitals or in routine primary care.
In today's climate of increasing scrutiny of health care
costs, an analysis of costs associated with the use of warfa-
rin is justified. The cost of warfarin per se is low, but INR
monitoring is likely to be associated with the use of large
resources. Firstly, because INR controls are both frequent
and resource-consuming for each patient concerned, and
secondly because treatment of warfarin is used in such
broad groups of patients. Furthermore, when complica-
tions occur, the treatment costs may rise substantially.
The cost-effectiveness has been studied in the prevention
of stroke in non-valvular atrial fibrillation, which is the
most common diagnosis for warfarin treatment [7-12].
These studies were performed in varying sub-sets of
patients, and the conclusions were that treatment with
warfarin was cost-effective (and sometimes cost-saving).
All studies included an estimate of the cost of warfarin
including costs of INR monitoring, but none reported the
detailed resource consumption related to INR monitor-
ing. The estimates were therefore either derived from tar-
iffs or gross estimates. All but two were carried out based
on data from the U.S. Of the non-U.S. studies, one was
from the U.K. and one from Sweden and both were based
on management of patients in a hospital setting [10,11].
To be able to estimate the costs of a particular health care
activity, various kinds of data from different sources must
be available. These include (i) the type and number of
health care or other resources that are involved, (ii) the
frequency by which such resources are used, (iii) the unit
costs of all individual cost items. In the case of the cost of
monitoring of warfarin, this is particularly complicated as
an INR control is not a defined entity, on the contrary it
might involve different kinds of resources depending on
different organisations and individual preferences. As
many of the patients under warfarin treatment are old and
frail, a certain proportion of the patients are subject to
domiciliary care.
The objective of this health economic assessment is to
estimate the health care cost of monitoring warfarin in
patients with CAF managed in primary care in Sweden.
Methods
The term "INR controls" is below defined as all aspect
involved in the monitoring of warfarin, including prepa-
rations and follow-up.
Frequency of INR controls
The frequency of INR controls during the initiation phase
and during established treatment was derived from two
retrospective studies of electronic patient records
[3,13,14]. Both studies were performed in Stockholm,
where patients on warfarin routinely are managed in pri-
mary care.
One study was performed on patients with CAF during the
initiation phase of warfarin treatment (the first three
months of treatment) [13]. Twelve primary health care
(PHC) centres from five different health care districts in
Stockholm County with a registered population of 203,
407 individuals included 144 patients.
In the other study, five PHC centres with a registered pop-
ulation of 75,146 participated. Twenty-five patients with
CAF, who had received a minimum of 30 days treatment
were randomly selected for a detailed review of the clinical
management of warfarin treatment [3,14]. Of those, five
patients had been treated for less than three months, one
had been on treatment for 11 months and 19 had been on
treatment for more than one year. All patients in the initi-
ation phase of treatment were excluded and data from the
remaining patients (n = 20) were used to represent the fre-
quency of INR controls in established patients, defined as
treatment for 12 months or more. Information on the fre-
quency of INR controls between four and 11 months
treatment was not available and an assumption of a linear
decline was applied, based on available data on the fre-
quency of INR controls during month three and month
12.
Resources consumed per INR control
The type and number of resources consumed at INR con-
trols were investigated in two Delphi-panel studies [15]).
In such panels standardised techniques are used to sys-
tematically collect and collate informed judgments from a
group of experts on specific questions or issues [16-20].
The respondents are anonymous to each other and the
study is performed in different rounds.
The respondents in both Delphi-panels were health care
personnel. One was performed in three rounds and had
the objective to study the resource use of patients whose
INR controls were carried out onsite at a PHC centre.BMC Family Practice 2007, 8:6 http://www.biomedcentral.com/1471-2296/8/6
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Thirty-four general practitioners (GPs) and 10 registered
nurses (RNs) from 34 PHC centres in Stockholm partici-
pated. The other Delphi panel investigated the resource
consumption for patients managed in home care. It was
performed in two rounds and 49 district nurses (DNs)
from all over Sweden were enrolled.
In the application of the Delphi technique in the studies
referred to in this article, the expert panel members were
randomly selected from GPs and RNs in primary care in
Stockholm and DNs in Sweden respectively. The panel
members were asked to estimate patient-related time
defined as time spent in preparation before the INR con-
trol, direct time spent together with the patient and fol-
low-up in connection with the control. Total patient-
related time spent by GPs and RNs respectively was
regarded as a reflection of resources used in INR controls,
apart from the work undertaken by laboratory staff and
the cost of transportation to and from patients in home
care, which were calculated separately. The costs were esti-
mated by multiplying the various resources by their
respective unit cost.
Unit cost calculation
Unit costs were based on data from 2003, estimated from
the perspective of the health care provider and expressed
in SEK (SEK 1 = € 0.11). Where costs have been reported
in $ or  in publications referenced in this article, the fol-
lowing exchange rates have been used; $1 = SEK 7.61 and
1 = SEK13.88. All exchange rates are as of June 30, 2004.
Cost of a patient-related hour
Gross payroll expenses were defined as the average annual
costs (salary, security fees and pensions) of GPs, RNs and
DNs in the County Council of Stockholm in Sweden. It
was SEK 868, 977 for a GP, SEK 382,508 for an RN and
SEK 412, 482 for a DN.
The average annual working hours in 2003 for full-time
employees in the health care sector was 1,576, which was
derived from a labour force survey performed by Statistics
Sweden (unpublished data). The patient-related time was
estimated to be 73% for the GPs. This figure was based on
a survey performed by The Swedish Institute for Health
Economics in 1999–2000 in which four different special-
ities were represented including GPs (n = 81) [21]. GPs
reported they spend 50% of their total working-hours in
face-to-face consultations with patients, and another 23%
of their time for administrative work directly related to
patients. This means 73% of the working-hours are allo-
cated to patient-related work. We estimated the patient-
related time for RNs and DNs to 85% based on the
assumption that patient-related time is greater for nurses
than for GPs.
Hence the average annual working hours of patient-
related time (Ann_pat_TIME) was estimated at 1,150
(0.73*1576) for GPs and 1,340 (0.85*1576) for RNs and
DNs.
The gross payroll expenses of a patient-related hour
(Gross_payroll_exp_pat_hour) was
Hence the "Gross_payroll_exp_pat_hour" was SEK 755
(868,977/1,150) for GPs, SEK 286 (382,508/1,340) for
RNs and SEK 308 (412,482/1,340) for DNs.
The balance-sheets of PHC centres include gross payroll
costs as well as overhead and administrative costs such as
rental and maintenance of the localities, capital costs and
telephone. These costs were denoted "other costs" and
were added to the payroll expenses to obtain a total cost
of a patient-related hour. The accounts of three PHC cen-
tres, one big (Gustavsberg), one middle-sized (Österåker)
and one small centre (Nyby), showed the average of
"other costs" was 40% of total cost.
The following formula was applied for calculation of the
total cost of a patient-related hour including
"Gross_payroll_exp_pat_hour " as well as "Other costs":
Thus the cost of a patient-related hour based on "Other
costs" being 40% was SEK 1259 (755/0.40) for a GP
('GP_hour_COST'), SEK 476 (286/0.40) for an RN
('RN_hour_COST') and SEK 513 (308/0.40) for a DN
(DN_hour_COST).
Sample and transportation costs
The work undertaken by laboratory staff was not investi-
gated in the Delphi panels. Therefore, tariff prices for tak-
ing the sample (SEK 80) and the analysis of the sample
(SEK 42) were used in the calculations. These costs were
derived from Nyby PHC centre.
The cost for car transportation was estimated to be SEK
2.50 per kilometre for a small or mid-sized car (Swedish
Consumer Agency in Stockholm).
Estimate of costs
Cost of INR controls at primary care centres
PHC centres were divided into such centres where GPs
were routinely assisted by an RN in the management of





Gross payroll pat hour
Proportion other costs
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GPs did not co-operate with an RN on a regular basis for
these controls. All costs are expressed as mean costs.
The cost of an INR control for GPs with an RN
('GPRN_control_ COST') was
['GP_hour_COST' * ('GPRN_TIME' + 'GPRN_exTIME')
+'RN_hour_COST' * ('RN_TIME' +'RN_exTIME')] +
'Sample_COST' + 'Analysis_COST'
where
'GP_hour_COST' and 'RN_hour_COST' have been
defined above,
'GPRN_TIME' = Mean time GPs, routinely assisted by a
nurse, spend on one INR control,
'GPRN_exTIME' = Mean extra time for GPs, routinely
assisted by an RN, when a patient does not appear for a
scheduled visit.
'RN_TIME' = Mean time nurses spend on one INR control,
'RN_exTIME' = Mean time for an RN when a patient does
not appear for a scheduled visit.
'Sample_COST' = Cost of taking the blood sample by lab-
oratory staff and
'Analysis_COST' = Cost of analysing the blood sample.
Similarly, the cost of an INR control when the GP was not
routinely assisted by an RN (GP_control_COST) was
* ['GP_hour_COST'* ('GP_TIME' + 'GP_exTIME')] +
'Sample_COST' + 'Analysis_COST'
where
'GP_hour_COST', 'Sample_COST' and 'Analysis_COST'
have been defined before and
'GP_TIME' = Mean time GPs, not routinely assisted by a
nurse, spend on one INR control,
'GP_exTIME' = Mean extra time for GPs, not routinely
assisted by an RN, when a patient does not appear for a
scheduled INR control.
Accordingly the total cost of an INR control when the
patient is managed onsite at a PHC centre
('PHC_control_COST) was
('GPRN_PROP' * 'GPRN_control_COST') + (GP_PROP *
GP_control_COST)
where
'GPRN_control_COST' and 'GP_control_COST' have
been defined before and
'GPRN_PROP' = Share of PHC centres where doctors are
routinely assisted by a nurse,
'GP_PROP = Share of GPs, not routinely assisted by a
nurse,
Cost of INR controls in home care
The total cost per INR home care visit
('HOME_control_COST') was:
['DN_hour_COST' * ('DN_TIME'+ 'DN_exTIME')] +
(Transp_COST * Transp_KM) + 'Analysis_COST'
where
'DN_hour_COST' and 'Analysis_COST' have been previ-
ously defined and where
'DN_TIME' = Mean time district nurses spend on one INR
control visit,
'Transp_COST' = Cost per kilometre by car (Swedish Con-
sumer Agency),
'Transp_KM' = Mean distance per INR control, return trip
and
'DN_exTIME' = Extra time per INR control due to INR con-
trol visits undertaken in vain.
Costs of INR control in primary care
Total cost of an INR control undertaken in primary care
('TOT_control_COST') was
('PHC_PROP' * 'PHC_control_COST') + ('HOME_PROP'
* 'HOME_control_COST')
where
'PHC_control_COST' and 'HOME_control_COST' have
been previously defined and
'PHC_PROP' = Proportion of INR controls undertaken at
a PHC centre and
'HOME_PROP' = Proportion of INR controls undertaken
in the patient's home.BMC Family Practice 2007, 8:6 http://www.biomedcentral.com/1471-2296/8/6
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Cost per patient
Total cost of INR controls during the initiation phase (first
three months of treatment), during the first year (includ-
ing the initiation phase) and during subsequent years of
treatment was obtained by multiplying
TOT_control_COST with the monitoring frequencies
observed in or derived from the two retrospective studies
on electronic patient records mentioned above [4,13,14].
Sensitivity analyses
Although this analysis provides the most accurate assess-
ment of the economic impact of INR controls in primary
care available to date, a number of uncertainties in the
estimates of resource use and unit costs were identified
and explored in a series of sensitivity analyses. The follow-
ing analyses were performed: (i) reduction/increase of the
time GPs (GPRN_TIME and GP_TIME and DNs
(DN_TIME) used for INR controls, (ii) the proportion of
home visits ('HOME_PROP') was lower/higher, (iii)
'Other costs' were lower/higher, (iv) the costs incurred by
laboratory staff ('Sample_COST') and analysis of the sam-
ple (Analysis_COST') were lower/higher.
Results
Frequency of INR controls
In the study on new patients on warfarin, 1,721 INR con-
trols were registered during a follow-up time of 12,688
days, resulting in an average number of INR controls dur-
ing the first three months of treatment of 12.38 (95% CI:
11.3–12.6) per patient [13]. The mean number of visits
during month three was 2.6.
The group of 20 established patients, from Nilsson et al
had a mean follow-up time of 0.55 years in the study [3]
and the annual frequency of visits was 16.18 (95%
CI:11.37–21.02, resulting in a mean number of 1.35 con-
trols per month.
The number of INR controls between month three and
month 12 was estimated at 17.14.
Resource use per INR controls
In 29% of the PHC centres, an RN was routinely involved
in the management of warfarin patients ('GPRN_PROP').
The mean time per INR control was 0.17 hours (10.1 min-
utes, 95% confidence interval, CI, 5.4; 14.8) for GPs
('GPRN_TIME') and 0.36 hours (21.4 minutes, 95% CI
11.0; 31.8) for the RNs ('RN_TIME'). The mean extra time
used for a missed appointment by a patient was 6.6 min-
utes (95% CI 0.3 – 12.9) for GPs and 4.9 minutes (95%
CI 2.0 – 7.8) for RNs. When taking the frequency of
missed visits into consideration, 11% for the GPs and
17% for the RNs, the mean extra time for "no-shows" was
0.012 hours/visit for the GPs ('GPRN_exTIME') and 0.014
hours/visit for the RNs ('RN_exTIME'), when allocated to
such INR controls which actually took place.
Where the GP managed INR controls without routinely
cooperating with an RN, the mean time used for a stand-
ard INR control was 0.29 hours (17.6 minutes, 95% CI
10.6;24.6) ('GP_TIME'). The extra time spent due the
patient's failure to show up for the scheduled visit was 5
minutes (95% CI 2.7 – 7.3). It was reported to happen in
11% of the scheduled visits and, accordingly, the mean
extra time per INR control was 0.009 hours
('GP_exTIME'). In addition to the work undertaken by the
GP, and RN where applicable, laboratory personnel was
involved in taking ('Sample_COST') and analysing the
blood sample ('Analysis_COST').
In the PHC centre Delphi study, the respondents reported
that 11.6% of their patients were unable to come to the
PHC centre for monitoring of INR. In these cases, the
monitoring of the patients was undertaken by DNs in
home care.
The study in domiciliary care demonstrated that the mean
time spent on INR controls in the patient's home was 1.47
hours (88.2 minutes, CI 95% 76.8 – 99.6 minutes)
('DN_TIME'). On average, the district nurse travelled 13.7
kilometres (95% CI 9.0;18.4) by car for each home visit
('Transp_KM'). In 8.2% of the times, the visit was in vain
as the patient was not at home. Each such visit took on
average 45 minutes (95% CI 33.1;56.1), representing a
mean of 0.059 hours per INR control ('DN_exTIME).
Of all INR controls in primary care, 88.4% were carried
out at a PHC centre ('PHC_PROP') and 11.6% in a
patient's home ('HOME_PROP').
Cost of monitoring warfarin
All variables are defined and referenced above.
Cost of INR controls at PHC
The cost of an INR control for GPs routinely assisted by a
nurse ('GPRN_control_ COST') was SEK 525 ([1,259 *
(0.168 +0.012) + 476 (0.357+0.014)] + 80 + 42)
The cost of an INR control for GPs working without rou-
tinely being assisted by an RN ('GP_control_COST') was:
SEK 503 ([1,259 * (0.293 + 0.009)] + 80 + 42)
The cost of an INR control carried out onsite at a PHC cen-
tre (PHCcontrolCO) was SEK 509 ((0.29 * 525) + (0.71 *
503))BMC Family Practice 2007, 8:6 http://www.biomedcentral.com/1471-2296/8/6
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Costs of INR control in home care
The cost of an INR control in home care
(HOME_control_COST) was SEK 861 (513* (1.470 +
0.059) + (2.50 * 13.7) + 42)
Cost of an INR control in primary care
The mean cost of an INR control in primary care
('TOT_control_COST') was SEK 550 ((0.884 * 509) +
(0.116* 861))
Total cost per patient
The costs of INR controls per patient based on varying
treatment periods are given in Table I.
Sensitivity analysis
The following analyses were performed: (i) the time used
for INR controls was reduced/increased by 5 minutes for
GPs ('GPRN_TIME' and 'GP_TIME') and 20 minutes for
DNs ('DN_TIME'), (ii) the proportion of home visits was
5% lower/20% higher ('HOME_PROP'), (iii) other cost
were 30% (lower)/50% (higher) (iv) the cost incurred by
laboratory staff ('Sample_COST') and analysis
('Analysis_COST') of the sample was 20% lower/20%
higher. The results are given in Table 2.
Discussion
We have used results from four studies to estimate the cost
of INR controls in patients on warfarin treatment man-
aged in primary care in Sweden. The results demonstrated
that substantial health care resources are consumed in the
effort to maintain the patients within their recommended
therapeutic INR intervals. In the base-case analysis, the
cost per monitoring visit was SEK 550 and the cost per
patient for the first three months of treatment was SEK
6,811. Furthermore the cost of INR controls for the first
year of treatment and the second year of treatment was
SEK 16,244 and 8,904 respectively. In sensitivity analyses,
the cost per INR control ranged from SEK 438 to 663,
where the lowest and highest figures reflected a scenario
where the time for the management of the patient had
been decreased and increased, respectively. Consequently,
the result of the analysis is sensitive to the correctness of
the time reported in the Delphi panel studies.
The annual costs for INR controls have in other studies
been reported to be between SEK 2,160 and 8,315 [7-11].
The cost per INR control was SEK 120 – 479 [7,10,11].
These studies had varying objectives, none of which were
to report on the cost of monitoring warfarin. Such costs
were therefore not computed in a detailed fashion, and
some of them may have been inadvertently omitted,
while we have been able to measure them in our study. In
previous studies the cost of monitoring warfarin was a
gross estimate applied as one out of many variables in
cost-effectiveness analyses, and few details were given on
how it was calculated. In some cases the cost represented
the tariff price of the actual test [10], while others had also
included a gross estimate of the cost of monitoring [7]. In
one study the cost of monitoring had been obtain from a
telephone survey of a few pharmacies and laboratories
[9]. The methods for estimating the costs related to INR
controls were thus subject to large variation. Moreover
they were derived from different health care settings and
based on estimates from a range of different countries. A
direct comparison with the results from our study is there-
fore inappropriate, although we note that the post-initial-
phase costs we obtain are similar to the upper bound
found in previous studies and that the costs of the initial
phase are quite high. It is also unsuitable to directly com-
pare our results with those of the Swedish study by Gus-
tafsson published in 1992, which reports the lowest
estimate of monitoring costs (SEK 120/visit, 2,160 annual
costs) [10] as it was based on an estimate of the costs in a
hospital setting, which may refer to an anticoagulation
clinic although not specifically stated.
The annual number of INR controls in patients with AF
has previously been reported to be 13.7 [7], 17.3 [11] and
18 [10] and thus they were in the same order of magni-
tude for established patients as in our study (16.18).
To our knowledge, the data in our study represent the
most detailed analysis of the resources consumed and
their costs in the monitoring of warfarin patients that is
available to date.
Although our approach represents a comprehensive
undertaking, the result has its limitations. The frequency
of visits was, for example, based on the actual number of
visits as registered in patient records. The observed
number may be underestimated as INR control may have
been carried out elsewhere, which may have been omitted
Table 1: Costs of INR controls/patient in primary care in Sweden. Cost/monitoring visit: SEK 550.
Length of period No. of INR moni toring visits Total cost (SEK)
Initiation phase 3 months 12.38 6,811
First treatment year, including initiation phase 12 months 29.52 16,244
Second year annual 16.18 8,904*
* undiscounted costBMC Family Practice 2007, 8:6 http://www.biomedcentral.com/1471-2296/8/6
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in the patient records. A further limitation of our study is
that it did not include societal costs, as costs incurred by
patients and or their care providers were not taken into
consideration. The same applies to the provision of trans-
portation for patients unable to organise their own travel
to the PHC.
Warfarin is used for the prevention of stroke in CAF-
patients. In a recent study the life-time direct costs of
stroke in Sweden was estimated to SEK 513,800, including
hospitalizations, drugs, outpatient visits, nursing home
and domestic aid [22]. The annual incidence of stroke in
CAF has been estimated to 5% [6], and warfarin has been
demonstrated to reduce this risk by approximately 60%
[23]. Taken together, this indicates a potential annual cost
reduction of SEK 15,000 per patient treated, due to the
reduced incidence of stroke. Our study shows that the cost
of monitoring patients after the initiation phase of treat-
ment is SEK 8,900 per year. Hence, the cost of such INR
controls might be completely offset by the reduction in
the cost of stroke even with the higher costs obtained in
this study as compared with previous research. This rough
calculation puts the cost of INR controls into perspective,
but as it disregards other aspects of the treatment, such as
costs and health consequences of complications and the
timing of events, the result of the calculation should inter-
preted with caution. A full health economic evaluation of
the cost-effectiveness of warfarin is a complex analysis,
where all relevant aspects of the treatment should be
included.
Conclusion
INR controls of patients on warfarin treatment in primary
care in Sweden represent a substantial cost to the health
care provider. The cost exceeds SEK 16,000 during the first
year of treatment and it amounts to almost SEK 9,000 per
patient during subsequent years. INR controls are particu-
larly costly when undertaken in home care. However, war-
farin prevents stroke in CAF, and the cost of monitoring
may be off-set by the reduced incidence of this disorder.
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1st yr 2nd yr*)
Base case 550 6,811 16,244 8,904
Shorter time
Doctors - 5 minutes
District nurses - 20 minutes 438 5,417 12,920 7,083
Longer time
Doctors + 5 minutes
District nurses + 20 minutes 663 8,204 19,567 10,726
Home visits
5% 527 6,524 15,559 8,529
20% 580 7,176 17,116 9,382
Other costs
30% 488 6,044 14,415 7,902
50% 637 7,884 18,804 10,308
Laboratory staff and analysis
Cost 20% lower 528 6,532 15,578 8,540
Cost 20% higher 573 7,090 16,909 9,269
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